Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Veris Gold Corp. Announces New Team Members to Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia

This site contains about 63,386 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   600   700   800   900   1,000   1,100   1,200   1,300   1,400   1,560   1,570   1,580   1,590   1,600   1,610   1,620   1,630   1,640   1,645   1,646   1,647   1,648   1,649   1,650   1,651   1,652   1,653   1,654   1,655   1,656   1,657   1,658   1,659   1,660   1,661   1,662   1,663   1,664   1,665   1,666   1,667   1,668   1,669   1,670   1,671   1,672   1,673   1,674   1,680   1,690   1,700   1,710   1,720   1,730   1,740   1,750   1,800   1,900   2,000   2,100   2,113 

2013/4/23
Veris Gold Corp. Announces New Team Members
Veris Gold Corp.
View more Veris Gold Corp. Announces New Team Members analysis
Sign-up for Veris Gold Corp. Announces New Team Members investment picks
2013/4/23
Veris Gold Corp. Announces New Team Members
Toronto Stock Exchange: VG VANCOUVER , April 23, 2013 /PRNewswire/ - Veris Gold Corp.
View more Veris Gold Corp. Announces New Team Members analysis
Sign-up for Veris Gold Corp. Announces New Team Members investment picks
2013/4/23
National Technical Systems Wins New Contract from Sandia National Laboratories
Continues Development of Harvester Project for Monitoring Radiation in the Atmosphere CALABASAS, Calif.
View more National Technical Systems Wins New Contract from Sandia National Laboratories analysis
Sign-up for National Technical Systems Wins New Contract from Sandia National Laboratories investment picks
2013/4/23
BioCryst to Announce First Quarter 2013 Financial Results May 7
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2013 financial results will be released on Tuesday, May 7, 2013.
View more BioCryst to Announce First Quarter 2013 Financial Results May 7 analysis
Sign-up for BioCryst to Announce First Quarter 2013 Financial Results May 7 investment picks
2013/4/23
EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013
FRANKFURT --The following is a summary of analysts' forecasts for AstraZeneca plc (AZN) first-quarter results, based on a poll of seven analysts conducted by Dow Jones Newswires (figures in million dollars, EPS and dividend in dollar, target price in pence, according to IFRS). Earnings figures are scheduled to be released April 25 .
View more EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013 analysis
Sign-up for EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013 investment picks
2013/4/23
Sainsbury's Market Share Rises to 16.9%, Tesco Slips to 29.9%
LONDON --Continuing recent trends J Sainsbury PLC (SBRY.LN) was the only one of the top four U.K. supermarkets to gain market share in the latest 12 weeks ended April 14 , while Tesco PLC (TSCO.LN) saw its share slide further to 29.9%. MAIN FACTS: -Tesco market share for 12 weeks ended April 14 29.9% (12 weeks ended April 15, 2012 : 30.7%) - J Sainsbury market share 16.9% (2012: 16.6%) -Asda market share 17.5% (2012: 17.6%) - Wm Morrison Supermarkets PLC (MRW.LN) market share 11.5% (2012: 11.9%) -Aldi and Lidl's joint market share 6.4% (2012: 5.5%); Aldi's share 3.4% (2012: 2.7%); Lidl's share 3.0% (2012: 2.8%). -Waitrose market share 4.9% (2011: 4.5%). -Grocery inflation stands at 3.8% for the 12 weeks ending April 14 .
View more Sainsbury's Market Share Rises to 16.9%, Tesco Slips to 29.9% analysis
Sign-up for Sainsbury's Market Share Rises to 16.9%, Tesco Slips to 29.9% investment picks
2013/4/23
Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) , a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta’s lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta’s proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, (ILC), which is the 48 th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in Amsterdam April 24-28, 2013.
View more Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL analysis
Sign-up for Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL investment picks
2013/4/23
New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1
- 96 percent of treatment-naive patients and 93 percent of prior null responders treated with AbbVie's investigational IFN-free, triple-DAA combination therapy achieve SVR24 - Additional analyses looks at response rates in patients with differing baseline factors including gender, viral load and fibrosis stage AMSTERDAM , April 23, 2013 /PRNewswire/ --  (NYSE: ABBV)   – Results from "Aviator,"  AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types.
View more New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 analysis
Sign-up for New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 investment picks
2013/4/23
UBS Updates Short-Term Gold Price Targets
Investment bank UBS on Tuesday updated its short-term price targets for gold following the precious metal's recent volatility.
View more UBS Updates Short-Term Gold Price Targets analysis
Sign-up for UBS Updates Short-Term Gold Price Targets investment picks
2013/4/23
Technician Demand Rises, Universal Technical Institute Funds $1 Million Scholarship Program
New scholarship program to support the immediate demand for technicians in the transportation industry SCOTTSDALE, Ariz.
View more Technician Demand Rises, Universal Technical Institute Funds $1 Million Scholarship Program analysis
Sign-up for Technician Demand Rises, Universal Technical Institute Funds $1 Million Scholarship Program investment picks
2013/4/23
Bristol Says Results of Hepatitis C Drug Trial are Positive
An experimental drug cocktail from Bristol-Myers Squibb Co.
View more Bristol Says Results of Hepatitis C Drug Trial are Positive analysis
Sign-up for Bristol Says Results of Hepatitis C Drug Trial are Positive investment picks
2013/4/23
Israeli Internet Translation Co Babylon Signs Agreement With Yahoo
JERUSALEM --Israeli online translation company Babylon Ltd.
View more Israeli Internet Translation Co Babylon Signs Agreement With Yahoo analysis
Sign-up for Israeli Internet Translation Co Babylon Signs Agreement With Yahoo investment picks
2013/4/23
Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company’s investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus (HCV) infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2013) in Amsterdam, The Netherlands.
View more Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C analysis
Sign-up for Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C investment picks
2013/4/23
Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress
- Phase 1 Results Further Demonstrate Potency of ACH-3102 in Genotypes 1a and 1b and Against Resistant HCV- AMSTERDAM, The Netherlands, April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of new data demonstrating the efficacy, safety, tolerability, and combinability of ACH-3102, a second-generation, pan-genotypic NS5A inhibitor, at the 48 th Annual Meeting of the European Association for the Study of the Liver (EASL) during the International Liver Congress 2013.
View more Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress analysis
Sign-up for Achillion Presents New Data on ACH-3102 to Treat Hepatitis C at the International Liver Congress investment picks
2013/4/23
InterOil Corporation Announces the Retirement of CEO Phil Mulacek
InterOil Corporation Announces the Retirement of CEO Phil Mulacek Canada NewsWire PORT MORESBY , Papua New Guinea and HOUSTON , April 23, 2013 /CNW/ - InterOil Corporation (NYSE:IOC) (POMSoX:IOC) ("InterOil") today announced the retirement of its founder and Chief Executive Officer, Phil Mulacek, effective April 30, 2013 .
View more InterOil Corporation Announces the Retirement of CEO Phil Mulacek analysis
Sign-up for InterOil Corporation Announces the Retirement of CEO Phil Mulacek investment picks
2013/4/23
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection Canada NewsWire The study results will be presented this week at the International Liver Congress, the 48 th annual meeting of the European Association for the Study of the Liver (EASL), in Amsterdam .
View more High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection analysis
Sign-up for High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection investment picks
2013/4/23
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection
Bristol-Myers Squibb Company (NYSE: BMY) today announced additional, interim Phase II data demonstrating that 12- and 24-week Triple DAA treatment regimens of daclatasvir (DCV), asunaprevir (ASV) and BMS-791325 (’325) achieved high rates of sustained virologic response (SVR) of up to 94%, in treatment-naïve, genotype 1 chronic hepatitis C patients, at time points ranging from 4 to 36 weeks post-treatment depending on the treatment group.
View more High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection analysis
Sign-up for High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection investment picks
2013/4/23
Polaris Reports Record First Quarter 2013 Results; EPS Increased 26% to $1.07 on 11% Sales Growth
Polaris Industries Inc. (NYSE: PII) today reported record first quarter net income of $75.5 million, or $1.07 per diluted share, for the quarter ended March 31, 2013.
View more Polaris Reports Record First Quarter 2013 Results; EPS Increased 26% to $1.07 on 11% Sales Growth analysis
Sign-up for Polaris Reports Record First Quarter 2013 Results; EPS Increased 26% to $1.07 on 11% Sales Growth investment picks
2013/4/23
Sensata Technologies Holding N.V. Announces First Quarter 2013 Results
--First quarter 2013 net revenue was $470.4 million, an increase of 5.6% from the fourth quarter 2012, and a decrease of (4.4)% from the first quarter 2012.
View more Sensata Technologies Holding N.V. Announces First Quarter 2013 Results analysis
Sign-up for Sensata Technologies Holding N.V. Announces First Quarter 2013 Results investment picks
2013/4/23
Take Your Tastebuds On A Staycation
NEW KEY LIME TREATS AND A STAYCATION GIVEAWAY FROM KRISPY KREME WINSTON SALEM, N.C. , April 23, 2013 /PRNewswire/ -- Summer sweetness is now in season with two new sun-kissed and handpicked Key Lime treats from Krispy Kreme®. Key Lime Cake and Key Lime Cheesecake Doughnuts are available April 22 through June 23, 2013 at participating Krispy Kreme US and Canadian locations.
View more Take Your Tastebuds On A Staycation analysis
Sign-up for Take Your Tastebuds On A Staycation investment picks
2013/4/23
Bayfield Drills 11.0m of 12.19 g/t Gold and 30.05 g/t Silver in Rainy River, NW Ontario
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0868393001&sourceType=1 http://www.ccnmatthews.com/logos/20110215-bayfield.jpg VANCOUVER, BRITISH COLUMBIA --
View more Bayfield Drills 11.0m of 12.19 g/t Gold and 30.05 g/t Silver in Rainy River, NW Ontario analysis
Sign-up for Bayfield Drills 11.0m of 12.19 g/t Gold and 30.05 g/t Silver in Rainy River, NW Ontario investment picks
2013/4/23
Central Concrete Announces First Environmental Product Declarations (EPDs) for Concrete Mixes in the United States
New LCA methodology delivers first EPD process that allows for the production of labels for every product online, in real-time SAN JOSE, Calif.
View more Central Concrete Announces First Environmental Product Declarations (EPDs) for Concrete Mixes in the United States analysis
Sign-up for Central Concrete Announces First Environmental Product Declarations (EPDs) for Concrete Mixes in the United States investment picks
2013/4/23
Home Bancorp Announces 2013 First Quarter Results
LAFAYETTE, La.
View more Home Bancorp Announces 2013 First Quarter Results analysis
Sign-up for Home Bancorp Announces 2013 First Quarter Results investment picks
2013/4/23
National Technical Systems Sets Date for Release of Fiscal 2013 Fourth Quarter, Year-End Results and Conference Call
CALABASAS, Calif.
View more National Technical Systems Sets Date for Release of Fiscal 2013 Fourth Quarter, Year-End Results and Conference Call analysis
Sign-up for National Technical Systems Sets Date for Release of Fiscal 2013 Fourth Quarter, Year-End Results and Conference Call investment picks
2013/4/23
Athabasca Oil Corporation to Hold 2013 First Quarter Conference Call and Annual General Meeting of Shareholders on April 30, 2013
Athabasca Oil Corporation to Hold 2013 First Quarter Conference Call and Annual General Meeting of Shareholders on April 30, 2013 Canada NewsWire An audio webcast of the conference call will also be available via Athabasca's website, www.atha.com or via the following URL: http://www.newswire.ca/en/webcast/detail/1127495/1229783 .
View more Athabasca Oil Corporation to Hold 2013 First Quarter Conference Call and Annual General Meeting of Shareholders on April 30, 2013 analysis
Sign-up for Athabasca Oil Corporation to Hold 2013 First Quarter Conference Call and Annual General Meeting of Shareholders on April 30, 2013 investment picks
2013/4/23
InterOil Corporation Announces the Retirement of CEO Phil Mulacek
PORT MORESBY, Papua New Guinea and HOUSTON , April 23, 2013 /PRNewswire/ -- InterOil Corporation (NYSE:IOC) (POMSoX:IOC) ("InterOil") today announced the retirement of its founder and Chief Executive Officer, Phil Mulacek , effective April 30, 2013 .
View more InterOil Corporation Announces the Retirement of CEO Phil Mulacek analysis
Sign-up for InterOil Corporation Announces the Retirement of CEO Phil Mulacek investment picks
2013/4/23
JinkoSolar Completes the Largest Rooftop PV System in a Desalination Plant in Partnership with Soltec Energias Renovables
SHANGHAI , April 23, 2013 /PRNewswire/ -- JinkoSolar Holding Co., Ltd.
View more JinkoSolar Completes the Largest Rooftop PV System in a Desalination Plant in Partnership with Soltec Energias Renovables analysis
Sign-up for JinkoSolar Completes the Largest Rooftop PV System in a Desalination Plant in Partnership with Soltec Energias Renovables investment picks
2013/4/23
Introducing the one and only Seagram Cider Mix Pack
Introducing the one and only Seagram Cider Mix Pack Canada NewsWire KITCHENER, ON, April 23, 2013 /CNW/ - Brick Brewing Co.
View more Introducing the one and only Seagram Cider Mix Pack analysis
Sign-up for Introducing the one and only Seagram Cider Mix Pack investment picks
2013/4/23
Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients
- ACH-3102 deemed safe and well-tolerated following 12 weeks of therapy - - High barrier to resistance demonstrated with no on-treatment virologic breakthrough observed - - Novel NS5A inhibitor study supports differentiated profile of ACH-3102 - NEW HAVEN, Conn., April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced updated interim safety and efficacy results, including early sustained virologic response (SVR4) data, from the pilot Phase 2 trial evaluating once-daily ACH-3102 plus ribavirin (RBV) in treatment-naïve patients with genotype 1b, IL28B CC subtype, chronic hepatitis C virus (HCV) infection.
View more Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients analysis
Sign-up for Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients investment picks
2013/4/23
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Food and Drug Administration (FDA) has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (R) (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG ≥200 mg/dL and <500 mg/dL) with mixed dyslipidemia.
View more Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia analysis
Sign-up for Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Veris Gold Corp. Announces New Team Members to Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.